Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
111M
-
Number of holders
-
224
-
Total 13F shares, excl. options
-
95.2M
-
Shares change
-
+3.29M
-
Total reported value, excl. options
-
$1.7B
-
Value change
-
+$20M
-
Put/Call ratio
-
0.12
-
Number of buys
-
107
-
Number of sells
-
-122
-
Price
-
$17.82
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q1 2025
296 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q1 2025.
NovoCure Ltd - Common Stock (NVCR) has 224 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 95.2M shares
of 111M outstanding shares and own 85.67% of the company stock.
Largest 10 shareholders include FMR LLC (16.5M shares), BlackRock, Inc. (13M shares), VANGUARD GROUP INC (11.3M shares), Capital International Investors (8.95M shares), Soleus Capital Management, L.P. (5.52M shares), Capital World Investors (5.22M shares), STATE STREET CORP (2.59M shares), GEODE CAPITAL MANAGEMENT, LLC (2.46M shares), MARSHALL WACE, LLP (1.81M shares), and UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC (1.78M shares).
This table shows the top 224 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.